Open access
Open access
Powered by Google Translator Translator

Oncology – Urological

RCT | No significant recurrence-free survival improvement with everolimus post-renal carcinoma surgery

3 Aug, 2023 | 13:17h | UTC

Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial – The Lancet (link to abstract – $ for full-text)

 


M-A | High-volume disease, T stage 4 show largest docetaxel benefit in prostate cancer

2 Aug, 2023 | 13:51h | UTC

Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials – The Lancet Oncology

Commentaries:

Meta-analysis of the Addition of Docetaxel to ADT in Metastatic Hormone-Sensitive Prostate Cancer – The ASCO Post

Disease Volume and T Stage Affect Docetaxel/ADT Efficacy in Prostate Cancer – Cancer Network

 

Commentary on Twitter

 


Single-arm study | Pembrolizumab plus Lenvatinib shows potential as first-line treatment for advanced non-clear-cell renal cell carcinoma

17 Jul, 2023 | 13:33h | UTC

Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)

 


RCT | Brachytherapy alone sufficient for intermediate-risk prostate cancer, no FFP improvement with additional EBRT

7 Jul, 2023 | 16:06h | UTC

Effect of Brachytherapy With External Beam Radiation Therapy Versus Brachytherapy Alone for Intermediate-Risk Prostate Cancer: NRG Oncology RTOG 0232 Randomized Clinical Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)

News Release: Addition of EBRT to brachytherapy did not improve outcomes for men with intermediate-risk prostate cancer, brachytherapy alone remains standard of care – NRG Oncology

 


M-A | Increased risk of cognitive toxic effects and fatigue in prostate cancer treatment with second-generation antiandrogens

16 Jun, 2023 | 14:00h | UTC

Association of Second-generation Antiandrogens With Cognitive and Functional Toxic Effects in Randomized Clinical Trials: A Systematic Review and Meta-analysis – JAMA Oncology (link to abstract – $ for full-text)

Commentary: Second-Generation Antiandrogens and Cognitive and Functional Toxicity in Patients With Prostate Cancer – The ASCO Post

 


RCT | Talazoparib plus enzalutamide prolongs radiographic PFS vs. enzalutamide alone in metastatic castration-resistant prostate cancer

14 Jun, 2023 | 14:29h | UTC

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial – The Lancet (link to abstract – $ for full-text)

News Release: Talazoparib Plus Enzalutamide Improves rPFS Over Placebo Plus Enzalutamide in First-Line Treatment for Patients with mCRPC – ESMO

 


Review | Screening for prostate cancer: evidence, ongoing trials, policies and knowledge gaps

13 Jun, 2023 | 13:52h | UTC

Screening for prostate cancer: evidence, ongoing trials, policies and knowledge gaps – BMJ Oncology

 


RCT | Atezolizumab and cabozantinib combo fails to outperform cabozantinib alone in renal cell carcinoma

7 Jun, 2023 | 13:54h | UTC

Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial – The Lancet (free registration required)

 

Commentary from the author on Twitter (thread – click for more)

 


M-A | Robot-assisted radical cystectomy versus open radical cystectomy

6 Jun, 2023 | 14:11h | UTC

Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy: A Systematic Review and Meta-analysis of Perioperative, Oncological, and Quality of Life Outcomes Using Randomized Controlled Trials – European Urology

 

Commentary from the author on Twitter (thread – click for more)

 


SR | Management of lymph node–positive penile cancer

24 May, 2023 | 13:03h | UTC

Management of Lymph Node–positive Penile Cancer: A Systematic Review – European Urology

 


Epidemiology of bladder cancer in 2023: a systematic review of risk factors

22 May, 2023 | 13:23h | UTC

Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors – European Urology

 


RCT | Cabozantinib addition to nivolumab and ipilimumab extends progression-free survival in renal-cell carcinoma

18 May, 2023 | 13:38h | UTC

Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Cabozantinib in Renal-Cell Carcinoma – NEJM Resident 360

 

Commentary on Twitter

 


M-A | First‐line therapy for adults with advanced renal cell carcinoma

12 May, 2023 | 13:33h | UTC

First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta‐analysis – Cochrane Library

Summary: Initial treatment for adults with advanced kidney cancer (renal cell carcinoma) – Cochrane Library

 


A review of modern imaging landscape for prostate cancer: a comprehensive clinical guide

9 May, 2023 | 14:34h | UTC

A Review of Modern Imaging Landscape for Prostate Cancer: A Comprehensive Clinical Guide – Journal of Clinical Medicine

 


RCT | Long-term survival benefit with abiraterone plus ADT in metastatic PC, but no advantage with enzalutamide association

8 May, 2023 | 13:02h | UTC

Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol – The Lancet Oncology

 

Commentary on Twitter

 


21-y clinical trial update | Effects of a PSA–based screening on morbidity and mortality of prostate cancer

5 May, 2023 | 14:56h | UTC

A Detailed Evaluation of the Effect of Prostate-specific Antigen–based Screening on Morbidity and Mortality of Prostate Cancer: 21-year Follow-up Results of the Rotterdam Section of the European Randomised Study of Screening for Prostate Cancer – European Urology

 


AUA/SUO Guideline | Part I – Early detection of prostate cancer: prostate cancer screening

2 May, 2023 | 13:49h | UTC

Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening – The Journal of Urology

See also: Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy – The Journal of Urology

 


AUA/SUO Guideline | Part II – Early detection of prostate cancer: considerations for a prostate biopsy

2 May, 2023 | 13:47h | UTC

Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy – The Journal of Urology

See also: Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening – The Journal of Urology

 


AUA/SUO Guideline | Diagnosis and management of non-metastatic upper tract urothelial carcinoma

2 May, 2023 | 13:44h | UTC

Diagnosis and Management of Non-Metastatic Upper Tract Urothelial Carcinoma: AUA/SUO Guideline – The Journal of Urology

 


AUA/SUO Guideline | Updates to Advanced Prostate Cancer

2 May, 2023 | 13:46h | UTC

Updates to Advanced Prostate Cancer: AUA/SUO Guideline (2023) – The Journal of Urology

 


Clinical trial 2y update | Avelumab first-line maintenance for advanced urothelial carcinoma

2 May, 2023 | 13:30h | UTC

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up – Journal of Clinical Oncology

Original Article: Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma – New England Journal of Medicine

 


Single-arm trial | Retroperitoneal lymph node dissection as first-line treatment for early metastatic seminoma shows 81% 2-Year RFS

28 Apr, 2023 | 13:02h | UTC

Surgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma With Limited Retroperitoneal Lymphadenopathy – Journal of Clinical Oncology

News Release: Surgery proves effective alternative to chemotherapy and radiation for early metastatic testicular cancer – Keck Medicine of USC

Commentary: Retroperitoneal Lymph Node Dissection for Early Metastatic Testicular Seminoma – The ASCO Post

 


Review | Risk stratification of low-risk prostate cancer: individualizing care in the era of active surveillance

25 Apr, 2023 | 14:35h | UTC

Risk Stratification of Low-Risk Prostate Cancer: Individualizing Care in the Era of Active Surveillance – Journal of Urology (free PDF for a limited period)

Related:

Low-Value Prostate-Specific Antigen Screening in Older Males – JAMA Network Open

RCT | Patient-reported outcomes 12 years after different treatments for localized prostate cancer

RCT | Localized prostate cancer treatment options have similar 15-year survival outcomes

 


Cardiovascular disease in testicular cancer survivors: Identification of risk factors and impact on quality of life

25 Apr, 2023 | 14:34h | UTC

Cardiovascular Disease in Testicular Cancer Survivors: Identification of Risk Factors and Impact on Quality of Life – Journal of Clinical Oncology

 


M-A | 5-alpha-reductase inhibitors are not associated with increased risk of mortality from prostate cancer

24 Apr, 2023 | 13:30h | UTC

Association Between 5α-Reductase Inhibitors and Prostate Cancer Mortality: A Systematic Review and Meta-analysis – JAMA Oncology (free for a limited period)

 

Commentary on Twitter

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.